The oral presentation will highlight SELVA, a 24-week, Phase 3, single-arm, baseline-controlled clinical trial of QTORIN™ rapamycin 3.9% anhydrous gel for the treatment of microcystic lymphatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback